The FDA package insert for ruxolitinib warns against the concomitant use of CYP3A4 inhibitors during treatment of GVHD, myelofibrosis, and polycythemia vera (PCV), which may cause neutropenia and thrombocytopenia. The gene discussed is CYP3A4; the disease is acquired polycythemia vera.